Abstract
Choline is a zwitter ion that is positively charged at certain pH, which necessitates transport systems to allow this amine to cross the phospholipid bilayer of cellular membranes. The solute carrier 44A1 (SLC44A1), also referred to as choline transporter-like protein 1 (CTL1), is a recently discovered choline transporter with an intermediate affinity for choline; this transport is Na+-independent and sensitive to inhibition by the drug hemicholinium-3. We highlight in this review the discovery and characterization of SLC44A1, describe its expression patterns and subcellular localization, and summarize evidence for the role of this choline transporter in the central nervous system.
Keywords: Choline transport, SLC44A1, choline transporter-like protein, hemicholinium, oxidative stress, cholinergic neurons, blood-brain barrier, cholinergic choline transport
Central Nervous System Agents in Medicinal Chemistry
Title:The Ubiquitous Choline Transporter SLC44A1
Volume: 12 Issue: 2
Author(s): Vera Michel and Marica Bakovic
Affiliation:
Keywords: Choline transport, SLC44A1, choline transporter-like protein, hemicholinium, oxidative stress, cholinergic neurons, blood-brain barrier, cholinergic choline transport
Abstract: Choline is a zwitter ion that is positively charged at certain pH, which necessitates transport systems to allow this amine to cross the phospholipid bilayer of cellular membranes. The solute carrier 44A1 (SLC44A1), also referred to as choline transporter-like protein 1 (CTL1), is a recently discovered choline transporter with an intermediate affinity for choline; this transport is Na+-independent and sensitive to inhibition by the drug hemicholinium-3. We highlight in this review the discovery and characterization of SLC44A1, describe its expression patterns and subcellular localization, and summarize evidence for the role of this choline transporter in the central nervous system.
Export Options
About this article
Cite this article as:
Michel Vera and Bakovic Marica, The Ubiquitous Choline Transporter SLC44A1, Central Nervous System Agents in Medicinal Chemistry 2012; 12 (2) . https://dx.doi.org/10.2174/187152412800792733
DOI https://dx.doi.org/10.2174/187152412800792733 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Functional and Molecular Ultrasound Imaging: Concepts and Contrast Agents
Current Medicinal Chemistry Glial Cell: A Potential Target for Cellular and Drug Based Therapy in Various CNS Diseases
Current Pharmaceutical Design Silibinin – A Promising New Treatment for Cancer
Anti-Cancer Agents in Medicinal Chemistry Therapy for Dominant Inherited Diseases by Allele-Specific RNA Interference: Successes and Pitfalls
Current Gene Therapy Combined Modality Treatment of Glioblastoma Multiforme: The Role of Temozolomide
Reviews on Recent Clinical Trials Specific Targeting of Akt Kinase Isoforms: Taking the Precise Path for Prevention and Treatment of Cancer
Current Drug Targets Viral Vectors in Cancer Immunotherapy: Which Vector for Which Strategy?
Current Gene Therapy CXCL12-CXCR4 Axis in Angiogenesis, Metastasis and Stem Cell Mobilization
Current Pharmaceutical Design Pharmacokinetics of Polymeric Micelles for Cancer Treatment
Current Drug Metabolism Development of NGR-Based Anti-Cancer Agents for Targeted Therapeutics and Imaging
Anti-Cancer Agents in Medicinal Chemistry Transmembrane Protein 166 and its Significance
Protein & Peptide Letters Diagnostic and Therapeutic Applications of Recombinant Antibodies:Targeting the Extra-Domain B of Fibronectin, A Marker of Tumor Angiogenesis
Current Pharmaceutical Design The Role of Shcbp1 in Signaling and Disease
Current Cancer Drug Targets Automated PET Radiotracer Manufacture on the BG75 System and Imaging Validation Studies of [18F]fluoromisonidazole ([18F]FMISO)
Current Radiopharmaceuticals G-Protein Signaling, Lipid Rafts and the Possible Sites of Action for the Antidepressant Effects of n-3 Polyunsaturated Fatty Acids
CNS & Neurological Disorders - Drug Targets Key Epigenetic Events Involved in the Maintenance of Breast Cancer Stem Cells
Current Stem Cell Research & Therapy Critical Steps in Tissue Processing in Histopathology
Recent Patents on DNA & Gene Sequences Gene Therapy: Optimising DNA Delivery to the Nucleus
Current Drug Targets Mitochondria in Cancer Stem Cells: A Target for Therapy
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Targeting the Ubiquitin Proteasome System: Beyond Proteasome Inhibition
Current Pharmaceutical Design